Cargando…
The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
The World Health Assembly in 2014 adopted a resolution that mandates both Member States and the WHO Secretariat to facilitate access to biotherapeutic products in a way that ensures their quality, safety and efficacy. The availability of biosimilars is expected to increase access to biotherapeutic p...
Autores principales: | Kang, Hye-Na, Thorpe, Robin, Knezevic, Ivana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254057/ https://www.ncbi.nlm.nih.gov/pubmed/32224101 http://dx.doi.org/10.1016/j.biologicals.2020.02.005 |
Ejemplares similares
-
Regulatory evaluation of biosimilars throughout their product life-cycle
por: Kang, Hye-Na, et al.
Publicado: (2018) -
Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study
por: Thorpe, Robin, et al.
Publicado: (2019) -
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience
por: Kurki, Pekka, et al.
Publicado: (2022) -
Regulatory challenges with biosimilars: an update from 20 countries
por: Kang, Hye‐Na, et al.
Publicado: (2020) -
WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019
por: Sheets, Rebecca, et al.
Publicado: (2020)